1. Amgen and Teva Pharmaceutical Industries each raised the price of two leukemia drugs, Blincyto and Treanda, respectively, for the second time this year. Amgen most recently increased the price of Blincyto by 3.9%, while Teva raised the price of Treanda by 4.5%. (MarketWatch)
2. Roche acquired mySugr, which markets a mobile app that allows users to enter information about their diabetes treatments and symptoms. (MedCityNews)
3. Proton-pump inhibitors, like AstraZeneca’s Nexium, are associated with an increased risk of early death, according to new research published in the British Medical Journal. (CNN)
4. Doctors are using Snapchat to transmit patient scans to each other. Physicians use the mobile app to record and share patient scans. (The Guardian)
5. Outcome Health has raised more than $600 million in funding from Goldman Sachs, CapitalG, and others. That estimate means that Outcome’s technology will likely be found in a majority of doctors’ offices within the next three years. (Forbes India)
